Amylyx Pharmaceuticals, Inc. (AMLX) Stock Price & How to Invest

Amylyx Pharmaceuticals develops treatments for neurodegenerative and endocrine conditions with few or no approved options. Its lead program is avexitide, a GLP-1 antagonist being tested in adults with post-bariatric hypoglycemia (PBH), a condition where people who have had Roux-en-Y gastric bypass surgery experience severe blood-sugar crashes. The registrational Phase 3 LUCIDITY trial enrolled 78 participants across a 16-week blinded period and met its pre-specified primary endpoint: a 55% reduction in Level 2 and Level 3 hypoglycemic events (p=0.000003). It also met secondary endpoints on Level 2 events, Level 3 events, and continuous glucose-monitoring outcomes, and avexitide was generally safe and well tolerated, consistent with earlier trials. All eligible patients moved into the open-label extension. Amylyx plans to present the topline data at ObesityWeek 2026 and to submit a New Drug Application before year-end 2026, with management discussing a possible 2027 launch. Behind it sit AMX0035 in Wolfram syndrome (a focused registrational Phase 3 was guided for the second half of 2026 after extended Phase 2 HELIOS data showed trends in pancreatic function and vision stabilization), AMX0114 in ALS (Phase 1 LUMINA data reported as safety-supportive), and AMX0318 in IND-enabling studies.

The investment picture is still concentrated, but the shape of the risk has changed. Amylyx has no meaningful product revenue today: its first approved drug, Relyvrio for ALS, was pulled from the market in 2024 after the confirmatory PHOENIX Phase 3 trial missed, which reset the company from commercial-stage back to clinical-stage and left a lasting credibility question that a clean LUCIDITY result goes some way toward answering. What it does have is a funded balance sheet, roughly $250.8 million in cash, cash equivalents and short-term investments as of June 30, 2026, with runway guided into 2028, which covers the filing, the review and a 2027 launch without a forced financing. The market has repriced the stock around that result: shares closed at $26.69 on October 16, 2026, up about 133.7% year to date and 75.9% over one year, for a market capitalization near $3.35 billion, though they have pulled back about 18% over the past month from a 52-week high of $41.14.

The concentration risk remains the dominant one: avexitide now carries nearly all of the equity value, and a positive 78-patient trial still leaves FDA review risk, label risk, and the possibility of requests for more data. Amylyx has already failed a confirmatory Phase 3 once, with Relyvrio withdrawn from the market in 2024, so execution credibility is still being rebuilt. Launching a drug for a rare condition is costly, and adoption depends on endocrinologists and payers treating the effect size as a clear improvement over cheap off-label options. The company generates no product revenue and lost about $152 million over the trailing twelve months, so any delay pushes it toward a financing that would dilute existing holders. The stock is volatile: it more than tripled from its 52-week low of $10.83 to $41.14 and then fell about 18% in the month to October 16, 2026, and an insider sold about $831,000 of shares in early October. There is also a legacy legal item: a securities class action tied to 2022 to 2023 Relyvrio launch statements was settled for $6.5 million, with preliminary court approval in May 2026 and a final approval hearing scheduled for September 2026.

11 analysts publish price targets on AMLX, averaging $42.64 against a $27.70 price as of November 2026, or +53.9%. The published targets run from $20.00 to $57.00, a wide spread, and the ratings split 11 buy, 1 hold, 0 sell. Over the last six months there have been 10 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full AMLX forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Amylyx Pharmaceuticals, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. From LUCIDITY data to an FDA filing. The 78-participant registrational trial met its primary endpoint with a 55% reduction in Level 2 and Level 3 hypoglycemic events and hit its key secondary measures. The most optimistic published target, $57.00, assumes this works close to its best case.

The case against. The concentration risk remains the dominant one: avexitide now carries nearly all of the equity value, and a positive 78-patient trial still leaves FDA review risk, label risk, and the possibility of requests for more data. The most pessimistic target, $20.00, is roughly what AMLX is worth if this bites instead.

Read the full bull and bear case on AMLX, including what would have to change to break either one. Walnut is not an investment adviser.

No. Amylyx Pharmaceuticals, Inc. (AMLX) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Amylyx Pharmaceuticals, Inc.'s investor relations page or your broker.

• Product revenue: None (Relyvrio withdrawn in 2024; consensus ~$28M for 2027)
• Cash and equivalents: ~$250.8M (June 30, 2026)
• Cash runway: Guided into 2028
• Net loss (TTM): ~$152M (EPS ~-$1.41)
• Operating cash burn (TTM): ~$127M
• Price to book: ~12x
• Market cap: ~$3.35B

Standard valuation multiples do not apply here because there is no revenue and no path to profitability without an approval. After the positive LUCIDITY result, the market capitalization of about $3.35 billion (October 16, 2026) sits on top of about $251 million of cash and a trailing loss near $152 million, so most of the value is the market's view of avexitide's approval odds and launch potential. The 11 analysts covering the stock have an average target near $43, and the Q3 2026 report on November 5 will update the cash line and filing timeline.

Other names that sit close to AMLX: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get AMLX exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so AMLX sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where AMLX fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Amylyx is a funded, single-asset biotech whose biggest risk, the LUCIDITY readout, came back positive; the story now turns on an FDA filing guided for year-end 2026, the review that follows, and whether a small company can launch a drug for a rare condition in 2027.

Whether AMLX is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is AMLX a buy or a sell?, and where the stock could go from here in the AMLX stock forecast.

For income investors, whether AMLX pays a dividend and how the payout looks is covered in does AMLX pay a dividend? And to weigh AMLX against a peer, read the full side-by-side comparisons: AMLX vs CRNX and AMLX vs CNS.